Inhibition of PARP enzymes has emerged as an important route to cancer therapy, since the combined effects of PARP inhibition and defective homologous recombination (HR) selectively kill BRCA-deficient tumour cells, whereas healthy cells remain largely unaffected (5,6). The gene discussed is PARP1; the disease is neoplasm.